Xencor (NASDAQ:XNCR) Given “Neutral” Rating at Piper Sandler
Piper Sandler reaffirmed their neutral rating on shares of Xencor (NASDAQ:XNCR – Free Report) in a research note released on Wednesday morning, Marketbeat reports. The brokerage currently has a $24.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $37.00. A number of other analysts have also recently commented on […]
More Stories
BigBear.ai (NYSE:BBAI) Trading Down 2.4% – What’s Next?
BigBear.ai Holdings, Inc. (NYSE:BBAI – Get Free Report)’s share price traded down 2.4% on Friday . The stock traded as...
Klondike Silver (CVE:KS) Stock Price Down 33.3% – What’s Next?
Klondike Silver Corp. (CVE:KS – Get Free Report)’s stock price fell 33.3% during trading on Friday . The company traded...
Microbot Medical (NASDAQ: MBOT) Announces $8.6 Million Registered Direct Offering
Microbot Medical Inc., a Delaware corporation, has recently disclosed an agreement involving Securities Purchase Agreements with investors for a registered...
La Rosa Holdings Corp. Completes Acquisition of Baxpi and Beaches Franchisees
La Rosa Holdings Corp. (NASDAQ: LRHC) recently announced the completion of its acquisition of Baxpi Holdings LLC and La Rosa...
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_
On January 10, 2025, NextCure, Inc. (NASDAQ: NXTC) made a significant announcement through a press release, indicating the dosing of...
ImmuCell Announces Strong Preliminary Sales Results for Q4 and Full Year 2024
ImmuCell Corporation (NASDAQ: ICCC) recently disclosed its preliminary, unaudited sales figures for the fourth quarter and full year that ended...